Research Papers:

Short- and long-term outcomes in onco-hematological patients admitted to the intensive care unit with classic factors of poor prognosis

Etienne Faucher _, Martin Cour, Vincent Jahandiez, Adeline Grateau, Thomas Baudry, Romain Hernu, Marie Simon, Jean-michel Robert, Mauricette Michallet and Laurent Argaud

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:22427-22438. https://doi.org/10.18632/oncotarget.7986

Metrics: PDF 1518 views  |   HTML 1874 views  |   ?  


Etienne Faucher1,2, Martin Cour1,2, Vincent Jahandiez1,2, Adeline Grateau1, Thomas Baudry1, Romain Hernu1, Marie Simon1, Jean-michel Robert1, Mauricette Michallet2,3, Laurent Argaud1,2

1Hospices civils de Lyon, Groupement hospitalier Edouard Herriot, Service de réanimation médicale, F-69003, Lyon, France

2Université de Lyon, Université Lyon 1, Faculté de médecine Lyon Est, F-69008, Lyon, France

3Hospices civils de Lyon, Centre hospitalier Lyon-Sud, Service d’hématologie, F-69310, Pierre-Bénite, France

Correspondence to:

Laurent Argaud, e-mail: [email protected]

Keywords: hematological malignancy, allogeneic hematopoietic stem cell transplantation, neutropenia, invasive mechanical ventilation, intensive care unit

Received: October 29, 2016     Accepted: February 23, 2016     Published: March 8, 2016


Although the overall mortality of patients admitted to intensive care units (ICU) with hematological malignancy has decreased over the years, some groups of patients still have low survival rates. We performed a monocentric retrospective study including all patients with hematological malignancy in a ten-year period, to identify factors related to the outcome for the whole cohort and for patients with allogeneic hematopoietic stem cell transplantation (HSCT), neutropenia, or those requiring invasive mechanical ventilation (IMV). A total of 418 patients with acute leukemia (n=239; 57%), myeloma (n=69; 17%), and lymphoma (n=53; 13%) were studied. Day-28 and 1-year mortality were 49% and 72%, respectively. The type of disease was not associated with outcome. The disease status was independentlty associated with 1-year mortality only. Independent predictors of day-28 mortality were IMV, renal replacement therapy (RRT), and performance status. For allogeneic HSCT recipients (n=116), neutropenic patients (n=124) and patients requiring IMV (n=196), day-28 and 1-year mortality were 52%, 54%, 74% and 81%, 78%, 87%, respectively. Multivariate analysis showed that IMV and RRT for allogeneic HSCT recipients, performance status and IMV for neutropenic patients, and RRT for patients requiring IMV were independently associated with short-term mortality (p<0.05).

These results suggest that IMV is the strongest predictor of mortality in hematological patients admitted to ICUs, whereas allogeneic HSCT and neutropenia do not worsen their short-term outcome.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7986